(Q46788198)

25 December 2017

title

Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy (English)

1 reference

25 December 2017

0 references

1 reference

invasive aspergillosis

1 reference

inferred from title

author

Dimitrios P Kontoyiannis

7

object named as

Dimitrios P Kontoyiannis

1 reference

25 December 2017

author name string

Ray Y Hachem

1

1 reference

25 December 2017

Maha R Boktour

2

1 reference

25 December 2017

Hend A Hanna

3

1 reference

25 December 2017

Rola N Husni

4

1 reference

25 December 2017

Harrys A Torres

5

1 reference

25 December 2017

Claude Afif

6

1 reference

25 December 2017

Issam I Raad

8

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

25 December 2017

number of pages

6

1 reference

inferred from page(s)

published in

Cancer

1 reference

25 December 2017

volume

112

1 reference

25 December 2017

issue

6

1 reference

25 December 2017

page(s)

1282-1287

1 reference

25 December 2017

Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

Lipid formulations of amphotericin B: recent progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Aspergillosis. Pathogenesis, clinical manifestations, and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Liposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Combination antifungal therapy for invasive aspergillosis - Is it indicated?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Combination antifungal therapy for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23311

7 January 2021

Identifiers

DOI

10.1002/CNCR.23311

1 reference

25 December 2017

PubMed ID

18224662

1 reference

25 December 2017